Omada Health Reports First Quarterly Profit, Fueled by GLP-1 Demand

Digital chronic care company Omada Health has reported its first profitable quarter, a significant milestone since going public less than a year ago. The company announced the results alongside its full-year 2025 earnings on Thursday, signaling a potential turning point for digital health companies striving for sustained financial success. This profitability appears closely linked to Omada’s growing involvement with the increasing demand for glucagon-like peptide-1 (GLP-1) medications, primarily used for weight loss and diabetes management.

Omada’s 2025 revenue reached $260 million, a 53% increase compared to the previous year. This figure exceeded even the high conclude of the preliminary results the company announced in January at the J.P. Morgan Healthcare Conference. Earlier, in August, shortly after its initial public offering, Omada had projected a maximum revenue of $241 million for the year.

The GLP-1 Factor and Omada’s Strategy

The surge in popularity of GLP-1 medications like Wegovy and Ozempic has created a ripple effect across the healthcare landscape. These drugs, initially developed for type 2 diabetes, have demonstrated significant weight loss benefits, leading to widespread demand – and, crucially for Omada, an opportunity to integrate them into its chronic care programs. Omada’s approach involves combining these medications with behavioral coaching and support, aiming to improve patient adherence and outcomes. The company’s success in capitalizing on this trend is reflected in its financial performance.

Mario Aguilar, a health tech correspondent at STAT, reported on Omada’s earnings, noting the company’s ability to seize the GLP-1 opportunity. Aguilar covers med tech startups, health apps, and digital therapies for STAT, and is the co-author of the STAT Health Tech newsletter. He can be reached on Signal at mariojoze.13.

What are GLP-1 Medications?

GLP-1s are a class of drugs that mimic a natural hormone in the body, glucagon-like peptide-1. This hormone plays a role in regulating blood sugar levels and appetite. GLP-1 medications work by increasing insulin release, decreasing glucagon secretion (which raises blood sugar), and slowing down gastric emptying, leading to a feeling of fullness. While effective, these medications are not without potential side effects, including nausea, vomiting, and diarrhea. Long-term effects are still being studied.

Beyond GLP-1: Omada’s Broader Chronic Care Programs

While GLP-1 medications are currently a key driver of growth, Omada’s business extends beyond weight management. The company offers programs addressing a range of chronic conditions, including diabetes, hypertension, and mental health. These programs typically involve a combination of remote monitoring, personalized coaching, and digital tools. Omada’s ability to diversify its offerings will be crucial for long-term sustainability, particularly as the GLP-1 market evolves and competition intensifies.

2026 Outlook and Investor Confidence

Omada has also provided earnings guidance for 2026, indicating continued growth as it leverages the demand for GLP-1 medications. This forward-looking statement has likely boosted investor confidence, demonstrating the company’s ability to not only achieve profitability but also to sustain it. However, it’s important to note that future performance is subject to various factors, including market dynamics, regulatory changes, and competition.

The Digital Health Landscape and the Pursuit of Profitability

Omada’s achievement is particularly noteworthy in the context of the broader digital health industry, where profitability has often proven elusive. Many digital health companies have struggled to demonstrate a clear path to sustainable revenue, relying heavily on venture capital funding. Omada’s success could signal a shift in the industry, with investors increasingly prioritizing companies that can generate consistent profits. The company’s experience may offer valuable lessons for other digital health startups navigating the challenges of scaling and achieving financial viability.

What to Consider Regarding Omada’s Financials

While the reported profit is encouraging, it’s important to consider the context. The company’s financial performance is heavily influenced by the current demand for GLP-1 medications, a market that is rapidly evolving. Factors such as the emergence of generic versions of these drugs, changes in insurance coverage, and the development of competing therapies could all impact Omada’s future revenue. The long-term effectiveness of Omada’s integrated approach – combining medication with behavioral support – remains to be fully established through rigorous research.

Looking ahead, continued monitoring of Omada’s financial performance, as well as ongoing research into the efficacy of its programs, will be essential. The company’s ability to adapt to changing market conditions and to demonstrate sustained value for patients and payers will ultimately determine its long-term success. For more information on digital health trends, you can explore resources from Rock Health, a venture fund dedicated to digital health.

You can also identify more information about Mario Aguilar, the STAT health tech correspondent who reported on Omada’s earnings, on his LinkedIn profile and through The Org.